<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;utm_source=Chrome&amp;v=2.18.0.post9+e462414&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20241211231418&amp;fc=20230708114047
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;utm_source=Chrome&amp;v=2.18.0.post9+e462414&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20241211231418&amp;fc=20230708114047" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Thu, 12 Dec 2024 04:14:18 +0000</lastbuilddate>
<pubDate>Wed, 11 Dec 2024 06:00:00 -0500</pubDate>
<ttl>120</ttl>
<item>
<title>Mediterranean diet, neutrophil count, and carotid intima-media thickness in secondary prevention: the CORDIOPREV study</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39661486/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241211231418&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: These findings suggest that neutrophils may represent a promising target for preventing atherosclerosis. A Mediterranean diet could serve as an effective dietary strategy to reduce neutrophil levels and potentially slow the progression of atherosclerosis, offering a new neutrophil-reducing therapy concept. Further research is essential to gain deeper insights into the role of neutrophils in the pathophysiology of atherosclerotic cardiovascular disease in humans.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Dec 11:ehae836. doi: 10.1093/eurheartj/ehae836. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Several studies have supported the role of innate immune system as a key factor in the sterile inflammation underlying the pathophysiology of atherosclerosis in mice. However, its involvement in humans remains unclear. This study aimed to explore the association between neutrophil count, and the intima-media thickness of common carotid arteries (IMT-CC), as well as the potential impact of long-term dietary interventions on these associations.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: A comprehensive analysis was conducted within the framework of the CORDIOPREV study, a long-term secondary prevention study involving dietary interventions with either a Mediterranean or a low-fat diet. The study evaluated the relationship between absolute neutrophil count and neutrophil-related ratios with IMT-CC at baseline and after 5 and 7 years of dietary intervention.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: At baseline, patients in the highest tertile of neutrophil count had a higher IMT-CC and number of carotid plaques, when compared to lowest tertile (P &lt; .01 and P &lt; .05, respectively). Logistic regression analyses supported this association. Elevated neutrophil count, neutrophil-to-erythrocyte ratio, and neutrophil-to-HDL ratio were associated with an increased likelihood of having an IMT-CC >;.9 mm {odds ratio (OR) 1.17 [95% confidence interval (CI) 1.04-1.35], OR 2.21 (95% CI 1.24-4.12), and OR 1.96 (95% CI 1.09-3.55), respectively}, after adjustment for all variables, which was corroborated by linear regression. Furthermore, a linear mixed-effect model analysis from a longitudinal analysis spanning 5 and 7 years revealed an increase in 1 unit of neutrophils/μl at these time points was associated with a mean increase of .004 (.002) mm in the IMT-CC (P = .031) after adjustment for all variables. Interestingly, in patients exhibiting regression in IMT-CC after 7 years of follow-up, those following a Mediterranean diet showed a significant decrease in neutrophil count after 5 and 7 years (both with P &lt; .05), compared to baseline.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: These findings suggest that neutrophils may represent a promising target for preventing atherosclerosis. A Mediterranean diet could serve as an effective dietary strategy to reduce neutrophil levels and potentially slow the progression of atherosclerosis, offering a new neutrophil-reducing therapy concept. Further research is essential to gain deeper insights into the role of neutrophils in the pathophysiology of atherosclerotic cardiovascular disease in humans.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39661486/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241211231418&v=2.18.0.post9+e462414">39661486</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae836>10.1093/eurheartj/ehae836</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39661486</guid>
<pubDate>Wed, 11 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Hatim Boughanem</dc:creator>
<dc:creator>José D Torres-Peña</dc:creator>
<dc:creator>Antonio Pablo Arenas-de Larriva</dc:creator>
<dc:creator>Juan L Romero-Cabrera</dc:creator>
<dc:creator>Purificación Gómez-Luna</dc:creator>
<dc:creator>Laura Martín-Piedra</dc:creator>
<dc:creator>Fernando Rodríguez-Cantalejo</dc:creator>
<dc:creator>Francisco J Tinahones</dc:creator>
<dc:creator>Elena M Yubero Serrano</dc:creator>
<dc:creator>Oliver Soehnlein</dc:creator>
<dc:creator>Pablo Perez-Martinez</dc:creator>
<dc:creator>Javier Delgado-Lista</dc:creator>
<dc:creator>José López-Miranda</dc:creator>
<dc:date>2024-12-11</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Mediterranean diet, neutrophil count, and carotid intima-media thickness in secondary prevention: the CORDIOPREV study</dc:title>
<dc:identifier>pmid:39661486</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae836</dc:identifier>
</item>
<item>
<title>Successful diagnosis and surgical treatment of tuberculous pericarditis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39661483/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241211231418&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Dec 11:ehae841. doi: 10.1093/eurheartj/ehae841. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39661483/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241211231418&v=2.18.0.post9+e462414">39661483</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae841>10.1093/eurheartj/ehae841</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39661483</guid>
<pubDate>Wed, 11 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Li Yang</dc:creator>
<dc:creator>Liqun He</dc:creator>
<dc:date>2024-12-11</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Successful diagnosis and surgical treatment of tuberculous pericarditis</dc:title>
<dc:identifier>pmid:39661483</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae841</dc:identifier>
</item>
<item>
<title>Prognostic impact of inducible ischaemia in ischaemic left ventricular dysfunction: the REVIVED-BCIS2 trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39661477/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241211231418&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Dec 11:ehae844. doi: 10.1093/eurheartj/ehae844. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39661477/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241211231418&v=2.18.0.post9+e462414">39661477</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae844>10.1093/eurheartj/ehae844</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39661477</guid>
<pubDate>Wed, 11 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Holly Morgan</dc:creator>
<dc:creator>Muhummad Sohaib Nazir</dc:creator>
<dc:creator>Matthew E Li Kam Wa</dc:creator>
<dc:creator>Gerry P McCann</dc:creator>
<dc:creator>John P Greenwood</dc:creator>
<dc:creator>Adam K McDiarmid</dc:creator>
<dc:creator>Matthew Dodd</dc:creator>
<dc:creator>Matthew Ryan</dc:creator>
<dc:creator>Divaka Perera</dc:creator>
<dc:creator>Amedeo Chiribiri</dc:creator>
<dc:date>2024-12-11</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Prognostic impact of inducible ischaemia in ischaemic left ventricular dysfunction: the REVIVED-BCIS2 trial</dc:title>
<dc:identifier>pmid:39661477</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae844</dc:identifier>
</item>
<item>
<title>Weekly Journal Scan: Pushing the boundaries of transcatheter aortic valve implantation in asymptomatic patients with severe aortic stenosis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39661473/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241211231418&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Dec 11:ehae839. doi: 10.1093/eurheartj/ehae839. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39661473/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241211231418&v=2.18.0.post9+e462414">39661473</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae839>10.1093/eurheartj/ehae839</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39661473</guid>
<pubDate>Wed, 11 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Rocco Vergallo</dc:creator>
<dc:creator>Daniela Pedicino</dc:creator>
<dc:date>2024-12-11</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Weekly Journal Scan: Pushing the boundaries of transcatheter aortic valve implantation in asymptomatic patients with severe aortic stenosis</dc:title>
<dc:identifier>pmid:39661473</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae839</dc:identifier>
</item>
<item>
<title>The '10 commandments' of the 2024 European Society of Cardiology guidelines for the management of chronic coronary syndromes</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39661412/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241211231418&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Dec 11:ehae778. doi: 10.1093/eurheartj/ehae778. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39661412/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241211231418&v=2.18.0.post9+e462414">39661412</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae778>10.1093/eurheartj/ehae778</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39661412</guid>
<pubDate>Wed, 11 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Christiaan J M Vrints</dc:creator>
<dc:creator>Felicita Andreotti</dc:creator>
<dc:date>2024-12-11</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>The '10 commandments' of the 2024 European Society of Cardiology guidelines for the management of chronic coronary syndromes</dc:title>
<dc:identifier>pmid:39661412</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae778</dc:identifier>
</item>
<item>
<title>Artificial intelligence in patients with atrial fibrillation to manage clinical complexity and comorbidities: the ARISTOTELES project</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39661409/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241211231418&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Dec 11:ehae792. doi: 10.1093/eurheartj/ehae792. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39661409/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241211231418&v=2.18.0.post9+e462414">39661409</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae792>10.1093/eurheartj/ehae792</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39661409</guid>
<pubDate>Wed, 11 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Giuseppe Boriani</dc:creator>
<dc:creator>Davide Antonio Mei</dc:creator>
<dc:creator>Gregory Y H Lip</dc:creator>
<dc:creator>ARISTOTELES Consortium</dc:creator>
<dc:date>2024-12-11</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Artificial intelligence in patients with atrial fibrillation to manage clinical complexity and comorbidities: the ARISTOTELES project</dc:title>
<dc:identifier>pmid:39661409</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae792</dc:identifier>
</item>
<item>
<title>European Research Council-funded grant: unveiling the effect of chemicals on lipids</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39661406/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241211231418&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Dec 11:ehae758. doi: 10.1093/eurheartj/ehae758. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39661406/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241211231418&v=2.18.0.post9+e462414">39661406</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae758>10.1093/eurheartj/ehae758</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39661406</guid>
<pubDate>Wed, 11 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Tina Kold Jensen</dc:creator>
<dc:creator>Iben Have Beck</dc:creator>
<dc:creator>Christian Lars Lund</dc:creator>
<dc:date>2024-12-11</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>European Research Council-funded grant: unveiling the effect of chemicals on lipids</dc:title>
<dc:identifier>pmid:39661406</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae758</dc:identifier>
</item>
<item>
<title>Angiotensin Receptor-Neprilysin Inhibitor Prescribing Patterns in Patients Hospitalized for Heart Failure</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39661383/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241211231418&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: Results of this cross-sectional study reveal that in the 7 years after FDA drug approval of sacubitril-valsartan, rates of ARNI or ACEI, ARB, or ARNI prescription at discharge increased, and rates of ACEI or ARB prescription decreased. Overall prescription of ARNI at discharge was 55.4% in eligible patients at the end of the study, suggesting remaining opportunity for continued improvement in ARNI prescription.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Dec 11. doi: 10.1001/jamacardio.2024.3815. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Angiotensin receptor-neprilysin inhibition (ARNI) improves mortality among patients with heart failure with reduced ejection fraction (HFrEF), ie, those with an EF of 40% or less.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To describe national longitudinal trends in ARNI prescribing patterns among hospitalized patients with HFrEF.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: Using data from the Get With The Guidelines-Heart Failure (GWTG-HF) registry, hospitalized patients with HFrEF at 614 participating hospitals were identified. Rates of ARNI, angiotensin converting enzyme inhibitor (ACEI), and angiotensin II receptor blocker (ARB) prescription at discharge were evaluated across 3 time periods. Adjusted logistic regression and piecewise logistic regression were used to evaluate the impact of publication dates on ARNI prescription rates.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">EXPOSURES: ARNI prescribing patterns in hospitalized patients with HFrEF.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: Rates of ARNI, ACEI, and ARB prescription at discharge were evaluated across 3 time periods as follows: (1) period 1 included the US Food and Drug Administration (FDA) approval of sacubitril-valsartan to the day before the PIONEER-HF (Comparison of Sacubitril-Valsartan vs Enalapril on Effect on N-Terminal Pro-Brain Natriuretic Peptide in Patients Stabilized From an Acute Heart Failure Episode) trial publication (July 7, 2015-November 10, 2018); (2) period 2 included the day of the PIONEER-HF trial publication to the day before publication of the 2021 Update to the 2017 Consensus for Optimization of Heart Failure Treatment (November 11, 2018-January 10, 2021); and (3) period 3 included the day of the 2021 update publication to the last available data at the time of analysis (January 11, 2021-December 31, 2022).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 114 333 hospitalized patients (mean [IQR] age, 67.0 [57.0-78.0] years; 74 765 male [65.4%]) were included in this study. Rates of ARNI prescribed at discharge increased from 1.1% (27 of 2451) during July 7, 2015, to September 30, 2015, to 55.4% (1957 of 3536) during October 1, 2022, to December 31, 2022. ACEI or ARB prescription at discharge fell from 88.3% (2612 of 2957) to 45.9% (2033 of 4434) over the same period, whereas ACEI, ARB, or ARNI prescription increased from 71.1% (2639 of 3713) to 84.7% (3990 of 4711). In adjusted logistic regression models, compared with period 1, patients discharged during period 2 and period 3 were found to have a 3.81-fold (95% CI, 3.65-3.98) and 9.15-fold (95% CI, 8.79-9.52) increased odds of ARNI prescription at discharge, and a 0.46 (95% CI, 0.45-0.48) and 0.25 (95% CI, 0.24-0.26) decreased odds of ACEI or ARB prescription at discharge.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: Results of this cross-sectional study reveal that in the 7 years after FDA drug approval of sacubitril-valsartan, rates of ARNI or ACEI, ARB, or ARNI prescription at discharge increased, and rates of ACEI or ARB prescription decreased. Overall prescription of ARNI at discharge was 55.4% in eligible patients at the end of the study, suggesting remaining opportunity for continued improvement in ARNI prescription.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39661383/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241211231418&v=2.18.0.post9+e462414">39661383</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.3815>10.1001/jamacardio.2024.3815</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39661383</guid>
<pubDate>Wed, 11 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Pratyaksh K Srivastava</dc:creator>
<dc:creator>Alexandra M Klomhaus</dc:creator>
<dc:creator>Stephen J Greene</dc:creator>
<dc:creator>Paul Heidenreich</dc:creator>
<dc:creator>Sabra C Lewsey</dc:creator>
<dc:creator>Clyde W Yancy</dc:creator>
<dc:creator>Gregg C Fonarow</dc:creator>
<dc:date>2024-12-11</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Angiotensin Receptor-Neprilysin Inhibitor Prescribing Patterns in Patients Hospitalized for Heart Failure</dc:title>
<dc:identifier>pmid:39661383</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.3815</dc:identifier>
</item>
<item>
<title>Pitavastatin, Procollagen Pathways, and Plaque Stabilization in Patients With HIV: A Secondary Analysis of the REPRIEVE Randomized Clinical Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39661372/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241211231418&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: Results of this secondary analysis of the REPRIEVE randomized clinical trial suggest that PCOLCE may be associated with the atherosclerotic plaque stabilization effects of statins by promoting collagen deposition in the extracellular matrix transforming vulnerable plaque phenotypes to more stable coronary lesions.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Dec 11. doi: 10.1001/jamacardio.2024.4115. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: In a mechanistic substudy of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) randomized clinical trial, pitavastatin reduced noncalcified plaque (NCP) volume, but specific protein and gene pathways contributing to changes in coronary plaque remain unknown.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To use targeted discovery proteomics and transcriptomics approaches to interrogate biological pathways beyond low-density lipoprotein cholesterol (LDL-C), relating statin outcomes to reduce NCP volume and promote plaque stabilization among people with HIV (PWH).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: This was a post hoc analysis of the double-blind, placebo-controlled, REPRIEVE randomized clinical trial. Participants underwent coronary computed tomography angiography (CTA), plasma protein analysis, and transcriptomic analysis at baseline and 2-year follow-up. The trial enrolled PWH from April 2015 to February 2018 at 31 US research sites. PWH without known cardiovascular diseases taking antiretroviral therapy and with low to moderate 10-year cardiovascular risk were eligible. Data analyses were conducted from October 2023 to February 2024.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">INTERVENTION: Oral pitavastatin calcium, 4 mg per day.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: Relative change in plasma proteomics, transcriptomics, and noncalcified plaque volume among those receiving treatment vs placebo.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Among 558 individuals (mean [SD] age, 51 [6] years; 455 male [82%]) included in the proteomics assessment, 272 (48.7%) received pitavastatin and 286 (51.3%) received placebo. After adjusting for false discovery rates, pitavastatin increased abundance of procollagen C-endopeptidase enhancer 1 (PCOLCE), neuropilin 1 (NRP-1), major histocompatibility complex class I polypeptide-related sequence A (MIC-A) and B (MIC-B), and decreased abundance of tissue factor pathway inhibitor (TFPI), tumor necrosis factor ligand superfamily member 10 (TRAIL), angiopoietin-related protein 3 (ANGPTL3), and mannose-binding protein C (MBL2). Among these proteins, the association of pitavastatin with PCOLCE (a rate-limiting enzyme of collagen deposition) was greatest, with an effect size of 24.3% (95% CI, 18.0%-30.8%; P &lt; .001). In a transcriptomic analysis, individual collagen genes and collagen gene sets showed increased expression. Among the 195 individuals with plaque at baseline (88 [45.1%] taking pitavastatin, 107 [54.9%] taking placebo), changes in NCP volume were most strongly associated with changes in PCOLCE (%change NCP volume/log2-fold change = -31.9%; 95% CI, -42.9% to -18.7%; P &lt; .001), independent of changes in LDL-C level. Increases in PCOLCE related most strongly to change in the fibro-fatty (&lt;130 Hounsfield units) component of NCP (%change fibro-fatty volume/log2-fold change = -38.5%; 95% CI, -58.1% to -9.7%; P = .01) with a directionally opposite, although nonsignificant, increase in calcified plaque (%change calcified volume/log2-fold change = 34.4%; 95% CI, -7.9% to 96.2%; P = .12).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: Results of this secondary analysis of the REPRIEVE randomized clinical trial suggest that PCOLCE may be associated with the atherosclerotic plaque stabilization effects of statins by promoting collagen deposition in the extracellular matrix transforming vulnerable plaque phenotypes to more stable coronary lesions.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02344290.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39661372/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241211231418&v=2.18.0.post9+e462414">39661372</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.4115>10.1001/jamacardio.2024.4115</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39661372</guid>
<pubDate>Wed, 11 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Márton Kolossváry</dc:creator>
<dc:creator>Samuel R Schnittman</dc:creator>
<dc:creator>Markella V Zanni</dc:creator>
<dc:creator>Kathleen V Fitch</dc:creator>
<dc:creator>Carl J Fichtenbaum</dc:creator>
<dc:creator>Judith A Aberg</dc:creator>
<dc:creator>Gerald S Bloomfield</dc:creator>
<dc:creator>Carlos D Malvestutto</dc:creator>
<dc:creator>Judith Currier</dc:creator>
<dc:creator>Marissa R Diggs</dc:creator>
<dc:creator>Christopher deFilippi</dc:creator>
<dc:creator>Allison Ross Eckard</dc:creator>
<dc:creator>Adrian Curran</dc:creator>
<dc:creator>Murat Centinbas</dc:creator>
<dc:creator>Ruslan Sadreyev</dc:creator>
<dc:creator>Borek Foldyna</dc:creator>
<dc:creator>Thomas Mayrhofer</dc:creator>
<dc:creator>Julia Karady</dc:creator>
<dc:creator>Jana Taron</dc:creator>
<dc:creator>Sara McCallum</dc:creator>
<dc:creator>Michael T Lu</dc:creator>
<dc:creator>Heather J Ribaudo</dc:creator>
<dc:creator>Pamela S Douglas</dc:creator>
<dc:creator>Steven K Grinspoon</dc:creator>
<dc:date>2024-12-11</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Pitavastatin, Procollagen Pathways, and Plaque Stabilization in Patients With HIV: A Secondary Analysis of the REPRIEVE Randomized Clinical Trial</dc:title>
<dc:identifier>pmid:39661372</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.4115</dc:identifier>
</item>
<item>
<title>In Vitro, but Not Yet In Vivo</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39661353/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241211231418&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Dec 11. doi: 10.1001/jamacardio.2024.4363. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39661353/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241211231418&v=2.18.0.post9+e462414">39661353</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.4363>10.1001/jamacardio.2024.4363</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39661353</guid>
<pubDate>Wed, 11 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Victoria R Bradford</dc:creator>
<dc:date>2024-12-11</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>In Vitro, but Not Yet In Vivo</dc:title>
<dc:identifier>pmid:39661353</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.4363</dc:identifier>
</item>
<item>
<title>Error in Figure 1</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39661084/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241211231418&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Dec 1;9(12):1174. doi: 10.1001/jamacardio.2024.4487.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39661084/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241211231418&v=2.18.0.post9+e462414">39661084</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.4487>10.1001/jamacardio.2024.4487</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39661084</guid>
<pubDate>Wed, 11 Dec 2024 06:00:00 -0500</pubDate>
<dc:date>2024-12-11</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Error in Figure 1</dc:title>
<dc:identifier>pmid:39661084</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.4487</dc:identifier>
</item>
<item>
<title>JAMA Cardiology</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39661083/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241211231418&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Dec 1;9(12):1068. doi: 10.1001/jamacardio.2023.3687.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39661083/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241211231418&v=2.18.0.post9+e462414">39661083</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.3687>10.1001/jamacardio.2023.3687</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39661083</guid>
<pubDate>Wed, 11 Dec 2024 06:00:00 -0500</pubDate>
<dc:date>2024-12-11</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>JAMA Cardiology</dc:title>
<dc:identifier>pmid:39661083</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.3687</dc:identifier>
</item>
<item>
<title>Illuminating data: how the new ESC Atlas can help chart a healthier future across Europe</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39660413/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241211231418&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Dec 11:ehae865. doi: 10.1093/eurheartj/ehae865. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39660413/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241211231418&v=2.18.0.post9+e462414">39660413</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae865>10.1093/eurheartj/ehae865</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39660413</guid>
<pubDate>Wed, 11 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Judith Ozkan</dc:creator>
<dc:date>2024-12-11</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Illuminating data: how the new ESC Atlas can help chart a healthier future across Europe</dc:title>
<dc:identifier>pmid:39660413</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae865</dc:identifier>
</item>
<item>
<title>Type 2 myocardial infarction: challenges in diagnosis and treatment</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39658094/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241211231418&amp;v=2.18.0.post9+e462414
      <description>The Fourth Universal Definition of Myocardial Infarction recommends a classification based on aetiology, in recognition that the underlying pathophysiology of myocardial infarction influences the approach to investigation and treatment. Type 1 myocardial infarction occurs due to atherosclerotic plaque rupture with thrombosis, whereas type 2 myocardial infarction occurs due to an imbalance in myocardial oxygen supply or unmet need in myocardial oxygen demand, without atherothrombosis, usually in...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Dec 10:ehae803. doi: 10.1093/eurheartj/ehae803. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The Fourth Universal Definition of Myocardial Infarction recommends a classification based on aetiology, in recognition that the underlying pathophysiology of myocardial infarction influences the approach to investigation and treatment. Type 1 myocardial infarction occurs due to atherosclerotic plaque rupture with thrombosis, whereas type 2 myocardial infarction occurs due to an imbalance in myocardial oxygen supply or unmet need in myocardial oxygen demand, without atherothrombosis, usually in the context of another acute illness. In this state-of-the-art review, the diagnosis, investigation, and treatment of patients with type 2 myocardial infarction are considered, with general advice for clinical practice and a consideration of future research directions.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39658094/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241211231418&v=2.18.0.post9+e462414">39658094</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae803>10.1093/eurheartj/ehae803</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39658094</guid>
<pubDate>Tue, 10 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Andrew R Chapman</dc:creator>
<dc:creator>Caelan Taggart</dc:creator>
<dc:creator>Jasper Boeddinghaus</dc:creator>
<dc:creator>Nicholas L Mills</dc:creator>
<dc:creator>Keith A A Fox</dc:creator>
<dc:date>2024-12-10</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Type 2 myocardial infarction: challenges in diagnosis and treatment</dc:title>
<dc:identifier>pmid:39658094</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae803</dc:identifier>
</item>
<item>
<title>Gold standard: Peter J. Schwartz honoured for pioneering work</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39658031/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241211231418&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Dec 10:ehae777. doi: 10.1093/eurheartj/ehae777. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39658031/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241211231418&v=2.18.0.post9+e462414">39658031</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae777>10.1093/eurheartj/ehae777</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39658031</guid>
<pubDate>Tue, 10 Dec 2024 06:00:00 -0500</pubDate>
<dc:date>2024-12-10</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Gold standard: Peter J. Schwartz honoured for pioneering work</dc:title>
<dc:identifier>pmid:39658031</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae777</dc:identifier>
</item>
<item>
<title>AI-ECG and prediction of new atrial fibrillation: when the heart tells the age</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39657904/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241211231418&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Dec 9:ehae809. doi: 10.1093/eurheartj/ehae809. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39657904/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241211231418&v=2.18.0.post9+e462414">39657904</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae809>10.1093/eurheartj/ehae809</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39657904</guid>
<pubDate>Tue, 10 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Antonio H Ribeiro</dc:creator>
<dc:creator>Antonio Luiz P Ribeiro</dc:creator>
<dc:date>2024-12-10</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>AI-ECG and prediction of new atrial fibrillation: when the heart tells the age</dc:title>
<dc:identifier>pmid:39657904</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae809</dc:identifier>
</item>
<item>
<title>Left Ventricular Ejection Fraction and Implantable Cardioverter-Defibrillator in Non-ischemic Heart Failure with Reduced Ejection Fraction: Insights from DANISH</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39657767/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241211231418&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Dec 10. doi: 10.1161/CIRCULATIONAHA.124.071777. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39657767/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241211231418&v=2.18.0.post9+e462414">39657767</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.071777>10.1161/CIRCULATIONAHA.124.071777</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39657767</guid>
<pubDate>Tue, 10 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Seiko N Doi</dc:creator>
<dc:creator>Jawad H Butt</dc:creator>
<dc:creator>Jens Jakob Thune</dc:creator>
<dc:creator>Jens C Nielsen</dc:creator>
<dc:creator>Jens Haarbo</dc:creator>
<dc:creator>Niels E Bruun</dc:creator>
<dc:creator>Line L Olesen</dc:creator>
<dc:creator>Lars Videbæk</dc:creator>
<dc:creator>Finn Gustafsson</dc:creator>
<dc:creator>Hans Eiskjær</dc:creator>
<dc:creator>Christian Hassager</dc:creator>
<dc:creator>Jesper H Svendsen</dc:creator>
<dc:creator>Dan E Høfsten</dc:creator>
<dc:creator>Steen Pehrson</dc:creator>
<dc:creator>Lars Køber</dc:creator>
<dc:date>2024-12-10</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Left Ventricular Ejection Fraction and Implantable Cardioverter-Defibrillator in Non-ischemic Heart Failure with Reduced Ejection Fraction: Insights from DANISH</dc:title>
<dc:identifier>pmid:39657767</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.071777</dc:identifier>
</item>
<item>
<title>Dual BACH1 regulation by complementary SCF-type E3 ligases</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39657677/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241211231418&amp;v=2.18.0.post9+e462414
      <description>Broad-complex, tramtrack, and bric-à-brac domain (BTB) and CNC homolog 1 (BACH1) is a key regulator of the cellular oxidative stress response and an oncogene that undergoes tight post-translational control by two distinct F-box ubiquitin ligases, SCF^(FBXO22) and SCF^(FBXL17). However, how both ligases recognize BACH1 under oxidative stress is unclear. In our study, we elucidate the mechanism by which FBXO22 recognizes a quaternary degron in a domain-swapped β-sheet of the BACH1 BTB dimer....</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Dec 6:S0092-8674(24)01322-9. doi: 10.1016/j.cell.2024.11.006. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Broad-complex, tramtrack, and bric-à-brac domain (BTB) and CNC homolog 1 (BACH1) is a key regulator of the cellular oxidative stress response and an oncogene that undergoes tight post-translational control by two distinct F-box ubiquitin ligases, SCF<sup>FBXO22</sup> and SCF<sup>FBXL17</sup>. However, how both ligases recognize BACH1 under oxidative stress is unclear. In our study, we elucidate the mechanism by which FBXO22 recognizes a quaternary degron in a domain-swapped β-sheet of the BACH1 BTB dimer. Cancer-associated mutations and cysteine modifications destabilize the degron and impair FBXO22 binding but simultaneously expose an otherwise shielded degron in the dimer interface, allowing FBXL17 to recognize BACH1 as a monomer. These findings shed light on a ligase switch mechanism that enables post-translational regulation of BACH1 by complementary ligases depending on the stability of its BTB domain. Our results provide mechanistic insights into the oxidative stress response and may spur therapeutic approaches for targeting oxidative stress-related disorders and cancer.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39657677/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241211231418&v=2.18.0.post9+e462414">39657677</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.11.006>10.1016/j.cell.2024.11.006</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39657677</guid>
<pubDate>Tue, 10 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Benedikt Goretzki</dc:creator>
<dc:creator>Maryam Khoshouei</dc:creator>
<dc:creator>Martin Schröder</dc:creator>
<dc:creator>Patrick Penner</dc:creator>
<dc:creator>Luca Egger</dc:creator>
<dc:creator>Christine Stephan</dc:creator>
<dc:creator>Dayana Argoti</dc:creator>
<dc:creator>Nele Dierlamm</dc:creator>
<dc:creator>Jimena Maria Rada</dc:creator>
<dc:creator>Sandra Kapps</dc:creator>
<dc:creator>Catrin Swantje Müller</dc:creator>
<dc:creator>Zacharias Thiel</dc:creator>
<dc:creator>Merve Mutlu</dc:creator>
<dc:creator>Claude Tschopp</dc:creator>
<dc:creator>David Furkert</dc:creator>
<dc:creator>Felix Freuler</dc:creator>
<dc:creator>Simon Haenni</dc:creator>
<dc:creator>Laurent Tenaillon</dc:creator>
<dc:creator>Britta Knapp</dc:creator>
<dc:creator>Alexandra Hinniger</dc:creator>
<dc:creator>Philipp Hoppe</dc:creator>
<dc:creator>Enrico Schmidt</dc:creator>
<dc:creator>Sascha Gutmann</dc:creator>
<dc:creator>Mario Iurlaro</dc:creator>
<dc:creator>Grigory Ryzhakov</dc:creator>
<dc:creator>César Fernández</dc:creator>
<dc:date>2024-12-10</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Dual BACH1 regulation by complementary SCF-type E3 ligases</dc:title>
<dc:identifier>pmid:39657677</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.11.006</dc:identifier>
</item>
<item>
<title>A commonly inherited human PCSK9 germline variant drives breast cancer metastasis via LRP1 receptor</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39657676/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241211231418&amp;v=2.18.0.post9+e462414
      <description>Identifying patients at risk for metastatic relapse is a critical medical need. We identified a common missense germline variant in proprotein convertase subtilisin/kexin type 9 (PCSK9) (rs562556, V474I) that is associated with reduced survival in multiple breast cancer patient cohorts. Genetic modeling of this gain-of-function single-nucleotide variant in mice revealed that it causally promotes breast cancer metastasis. Conversely, host PCSK9 deletion reduced metastatic colonization in multiple...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Dec 7:S0092-8674(24)01326-6. doi: 10.1016/j.cell.2024.11.009. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Identifying patients at risk for metastatic relapse is a critical medical need. We identified a common missense germline variant in proprotein convertase subtilisin/kexin type 9 (PCSK9) (rs562556, V474I) that is associated with reduced survival in multiple breast cancer patient cohorts. Genetic modeling of this gain-of-function single-nucleotide variant in mice revealed that it causally promotes breast cancer metastasis. Conversely, host PCSK9 deletion reduced metastatic colonization in multiple breast cancer models. Host PCSK9 promoted metastatic initiation events in lung and enhanced metastatic proliferative competence by targeting tumoral low-density lipoprotein receptor related protein 1 (LRP1) receptors, which repressed metastasis-promoting genes XAF1 and USP18. Antibody-mediated therapeutic inhibition of PCSK9 suppressed breast cancer metastasis in multiple models. In a large Swedish early-stage breast cancer cohort, rs562556 homozygotes had a 22% risk of distant metastatic relapse at 15 years, whereas non-homozygotes had a 2% risk. Our findings reveal that a commonly inherited genetic alteration governs breast cancer metastasis and predicts survival-uncovering a hereditary basis underlying breast cancer metastasis.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39657676/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241211231418&v=2.18.0.post9+e462414">39657676</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.11.009>10.1016/j.cell.2024.11.009</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39657676</guid>
<pubDate>Tue, 10 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Wenbin Mei</dc:creator>
<dc:creator>Schayan Faraj Tabrizi</dc:creator>
<dc:creator>Christopher Godina</dc:creator>
<dc:creator>Anthea F Lovisa</dc:creator>
<dc:creator>Karolin Isaksson</dc:creator>
<dc:creator>Helena Jernström</dc:creator>
<dc:creator>Sohail F Tavazoie</dc:creator>
<dc:date>2024-12-10</dc:date>
<dc:source>Cell</dc:source>
<dc:title>A commonly inherited human PCSK9 germline variant drives breast cancer metastasis via LRP1 receptor</dc:title>
<dc:identifier>pmid:39657676</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.11.009</dc:identifier>
</item>
<item>
<title>Focus on atrial fibrillation: role of atrioventricular node ablation, prediction by deep learning, and anticoagulation in device-detected arrhythmia</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39657597/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241211231418&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Dec 7;45(46):4873-4877. doi: 10.1093/eurheartj/ehae826.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39657597/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241211231418&v=2.18.0.post9+e462414">39657597</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae826>10.1093/eurheartj/ehae826</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39657597</guid>
<pubDate>Tue, 10 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Filippo Crea</dc:creator>
<dc:date>2024-12-10</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Focus on atrial fibrillation: role of atrioventricular node ablation, prediction by deep learning, and anticoagulation in device-detected arrhythmia</dc:title>
<dc:identifier>pmid:39657597</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae826</dc:identifier>
</item>
<item>
<title>A Manifesto from Global Heart Hub for early detection and diagnosis of cardiovascular disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39656480/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241211231418&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Dec 3:ehae455. doi: 10.1093/eurheartj/ehae455. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39656480/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241211231418&v=2.18.0.post9+e462414">39656480</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae455>10.1093/eurheartj/ehae455</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39656480</guid>
<pubDate>Tue, 10 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Fausto J Pinto</dc:creator>
<dc:creator>Ed Harding</dc:creator>
<dc:creator>Olive Fenton</dc:creator>
<dc:date>2024-12-10</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>A Manifesto from Global Heart Hub for early detection and diagnosis of cardiovascular disease</dc:title>
<dc:identifier>pmid:39656480</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae455</dc:identifier>
</item>





























</channel>
</rss>